Headache News and Research

Latest Headache News and Research

Cedars-Sinai neurosurgeon successfully performs CSF repair surgery on patient

When Elizabeth "Beth" Johnson stood up from working at her computer Oct. 28, she noticed "a kind of funny feeling" in the back of her neck. By Nov. 2, the sensation had become an excruciating headache that came on whenever she tried to stand or sit upright.

28 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Nurses in emergency care must be trained to recognise symptoms of meningococcal septicaemia

Nurses working in emergency care environments must be trained to recognise the atypical signs and symptoms of meningococcal septicaemia.

26 Feb 2014

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.

25 Feb 2014

Onset Dermatologics launches 75mg strength of MINOCIN pellet-filled capsules to treat bacterial infections

Onset Dermatologics, a leader in developing and commercializing prescription products for improving skin health, today announced the launch of a 75mg strength of MINOCIN (minocycline hydrochloride) Pellet-Filled Capsules.

25 Feb 2014

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.

25 Feb 2014

Dreams and delusions are associated with faulty "reality testing", shows research

New research from the University of Adelaide has delved into the reasons why some people are unable to break free of their delusions, despite overwhelming evidence explaining the delusion isn't real.

21 Feb 2014

XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.

20 Feb 2014

Stress does lead to more headaches, new study reveals

A new study provides evidence for what many people who experience headache have long suspected—having more stress in your life leads to more headaches. The study released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

20 Feb 2014

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases.

20 Feb 2014

Ticks infected with the bacterium that causes Lyme disease widespread in San Francisco Bay Area

As winter turns to spring and many Northern Californians plan outdoor adventures, a mysterious, potentially debilitating threat looms.

19 Feb 2014

New research may provide insight on how dengue virus gains entry into cells

Dengue fever, an infectious tropical disease caused by a mosquito-borne virus, afflicts millions of people each year, causing fever, headache, muscle and joint pains and a characteristic skin rash. In some people the disease progresses to a severe, often fatal, form known as dengue hemorrhagic fever.

18 Feb 2014

Scientists measure how well football helmet designs protected against traumatic brain injury

A new study finds that football helmets currently used on the field may do little to protect against hits to the side of the head, or rotational force, an often dangerous source of brain injury and encephalopathy.

18 Feb 2014

Valproic acid metabolism and obesity: an interview with Dr. Namandjé Bumpus, Johns Hopkins Medicine

Valproic acid is one of the most widely prescribed drugs for the treatment of epilepsy. It has also been shown to be effective for the treatment of mood disorders and migraine headaches.

17 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby - twice as long as previously recognized, according to a large study presented at the American Stroke Association's International Stroke Conference 2014.

14 Feb 2014

Parents and doctors must be aware and prepared to treat strokes in children

Parents and healthcare professionals must be aware that children can have strokes and be prepared to respond to symptoms, according to research presented at the American Stroke Association's International Stroke Conference 2014.

13 Feb 2014

Stroke hospitalization and death rates associated with weather changes

Stroke hospitalization and death rates may rise and fall with changes in environmental temperature and dew point, according to research presented at the American Stroke Association's International Stroke Conference 2014.

12 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt plc, a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc.

11 Feb 2014

Headache News and Research

Latest Headache News and Research

Cedars-Sinai neurosurgeon successfully performs CSF repair surgery on patient

FDA approves KALYDECO for people with cystic fibrosis

Nurses in emergency care must be trained to recognise symptoms of meningococcal septicaemia

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Onset Dermatologics launches 75mg strength of MINOCIN pellet-filled capsules to treat bacterial infections

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Dreams and delusions are associated with faulty "reality testing", shows research

XenoPort reports net loss of $19.1 million for fourth quarter 2013

Stress does lead to more headaches, new study reveals

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Ticks infected with the bacterium that causes Lyme disease widespread in San Francisco Bay Area

New research may provide insight on how dengue virus gains entry into cells

Scientists measure how well football helmet designs protected against traumatic brain injury

Valproic acid metabolism and obesity: an interview with Dr. Namandjé Bumpus, Johns Hopkins Medicine

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

Parents and doctors must be aware and prepared to treat strokes in children

Stroke hospitalization and death rates associated with weather changes

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in